Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTRA-9620 in Infants With Short Bowel Syndrome
NCT02865122Phase 3Terminated
- Sponsor
- Elgan Pharma
- Start
- Mar 2017
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of regular human insulin in short bowel syndrome (SBS), sponsored by Elgan Pharma. Started Mar 2017; status: terminated.
02
Drugs
regular human insulin
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT02865122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02865122.